Antimicrobial Resistance - Breakthrough Innovation and Breaking Barriers
Antimicrobial resistance (AMR) is a growing public health concern and a threat to global health security. 700,000 people die each year from AMR infections, and it is estimated that by 2050, AMR infections could cause 10 million deaths per year1.
Multi-drug resistant (MDR) bacteria are a particular threat as existing antibiotics are becoming ineffective. During this webinar we will explore the challenges and opportunities in developing new interventions to prevent and treat bacterial infections including new antibiotics, vaccines and non-traditional modalities.
So why aren’t (enough) new antibiotics being developed to add to our arsenal? An important reason is that the traditional business model for innovative pharmaceutical products doesn’t apply. If you were to develop a new antibiotic today, it might be shelved to use in case of an emergency only, because introducing new antibiotics might give rise to more resistance and even stronger pathogens. In addition, it is a long, complicated, and risky process to develop new antibiotics. There are other potential barriers. Do our health care systems fully recognize the value of new antibiotics? Are there enough late-stage investments in antibiotic development?
Other innovations might prevent or treat MDR bacterial infections without increasing antibiotic resistance. These interventions include bacterial vaccines and disruptive, non-traditional modalities such as phage and CRISPR. How can we pave the road for their successful development and introduction?
The global community of public and private organizations, non-profits, governments, and life science innovators are rallying around the AMR challenge. View the recording as thought leaders share their views on the challenges surrounding this global health threat and the potential solutions. Topics include:
- Priority MDR bacterial pathogens of interest
- Potential interventions to prevent and treat MDR bacterial infections
- Barriers in the development and commercialization pathway
- The need for policy change to address these barriers
- The potential roles of various organizations and public-private partnerships
*This program is part of BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA).
1) WHO website, accessed on 3 June 2021
Please note: This webinar will be a rebroadcast of the recording which took place September 15, 2021.
You are watching a rebroadcast of the webinar. There will not be a live Q&A session following the presentation. If you have any questions for the speakers, please email [email protected]
DISCLAIMER: The information on this webpage, including in the videos, is proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (“JJI”) and is for informational purposes only. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson or its affiliates. The information presented in the videos is specific and applicable to region in which the original presentation took place. Many videos contain information from, or sessions given by, third parties. Please note that only those third parties that provide this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in these videos, and JJI makes no representations, warranties, or assurances, express or implied, as to the content or the information presented and is not responsible for any use of this information by you.